Aytu BioPharma reported a decrease in total net revenue to $22.1 million compared to $27.7 million in the previous year, primarily due to the wind down of the Consumer Health segment. The Rx segment's net revenue was $17.8 million, with ADHD product revenue increasing by 31%. The company reported a net loss of $8.1 million, impacted by a $5.9 million loss on derivative warrant liabilities.
Total net revenue was $22.1 million, a decrease from $27.7 million year-over-year, mainly due to the planned wind down of the Consumer Health segment.
ADHD product net revenue increased by 31% to $15.1 million compared to $11.6 million in the prior year.
The Company’s Rx segment net revenue was $17.8 million compared to $18.7 million in the year-ago quarter.
Cash and cash equivalents totaled $20.0 million as of September 30, 2023.
Aytu BioPharma is focusing on its Rx segment and winding down its Consumer Health segment to drive long-term shareholder value. The company expects to sell through the remaining Consumer Health inventory, resulting in approximately neutral Adjusted EBITDA for the segment in fiscal 2024.
Analyze how earnings announcements historically affect stock price performance